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Abstract
Purpose To provide an overview of and discuss newly
authorised medicines with an improved efficacy.
Methods This analysis focussed on new medicines with an
improved efficacy based on the results of randomised active
control trials. Information on comparative efficacy was
obtained from the European Medicines Agency European
Public Assessment Reports.
Results Between 1999 and 2005 we identified 122 new medi-
cines with a new active substance. Of these, 13 (10%) were
s h o w nt ob es u p e r i o rt oa l r e a d yavailable medicines in terms a
statistically significant difference in primary clinical endpoints.
Conclusions A proven advantage in efficacy at an early
stage of drug development is the exception rather than the
rule. The absence of evidence demonstrating differences
between medicines does not necessarily mean that there are
no actual differences. Optimal pharmacotherapy would
benefit from more comparative research in the development
of new medicines. The results of comparative trials need to
be critically evaluated for their specific value in clinical
practice. To this end, prescription data may be helpful.
Keywords Added therapeutic value.Comparative
information.Market authorisation.Randomised active
control trials.Superiority trials
Introduction
The ultimate goal of developing new medicines should be
an improvement in treatment—namely, the new medicine
should provide some additional clinical benefit to patients
compared to those currently available [1–4]. This added
therapeutic value may lie in one or any of a number of
different properties, such as efficacy, safety, applicability,
convenience of administration, among others. Of these,
efficacy and safety are considered to be the most impor-
tant: the new medicine should be more efficacious and/or
safer.
Demonstrating any improvement is not an explicit
condition for being granted marketing authorisation. Data
on quality, efficacy and safety are therefore needed in order
to demonstrate a favourable benefit/risk ratio when treating
a patient for the claimed therapeutic indication. In this
context, placebo controlled trials provide robust evidence
[5, 6]. However, in the case of new medicines for which
good alternatives are available, the regulatory authorities
need to be sure that the possibility has been excluded that
patients are treated with a product that is less efficacious or
less safe [7]. Files submitted to the regulatory authorities
can include studies that demonstrate efficacy by confirming
the absence of a difference (equivalence trial) or by showing
that the new medicine is no worse than an existing medicine
(noninferiority trial). Efficacy can also be demonstrated by
showing an improved efficacy compared with a medicine
already being used in clinical practice for the same claimed
therapeutic indication (superiority trial). It goes without saying
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provide information on how new medicines, accurately
estimated for their efficacy, contribute to an improvement in
treatment options for patients. Unfortunately, statistics on the
extent of superior medicines as a result of the marketing
authorisation process are scarce.
The aim of this study is to provide an overview of and to
discuss newly authorised medicines with an improved
efficacy.
Methods
This study was an in-depth analysis of data from a previous
study on the availability of comparative information on new
medicines at the time European market authorisation was
granted [8]. We therefore analysed the European Public
Assessment Reports (EPARs) of the European Medicines
Agency (EMEA) between 1999 and 2005 on new medicines
with a new active substance [9]. The analysis focussed on
new medicines with an improved efficacy based on
randomised active control trials (RaCTs). Data on the RaCTs
extracted from the EPARs included therapeutic indication,
objective, comparator, design, clinical endpoints, results and
the conclusion of the Committee for Medicinal Products for
Human Use (CHMP) on comparative efficacy.
Results
We identified 122 medicines with a new active substance
that had been newly authorised between 1999 and 2005; of
these, 58 (48%) had been compared with existing medicines.
In total, 153 main/pivotal active control trials had been
performed. The objective of 15 (10%) of these was to show
superiority—but this was not possible in four trials. For
bimatoprost, fondaparinux, peginterferon alfa-2a, peginter-
feron alfa-2b and tipranavir, the objective of demonstrating
superiority was realised. A difference in efficacy was also
demonstrated in 13 trials with the primary objective to show
noninferiorityorequivalence.The medicines were considered
to be superior when a statistically significant difference in
primary clinical endpoints was demonstrated. In total,
superiority was demonstrated in 24 trials for 13 (10%) new
medicines in the period 1999–2005 (see Table 1).
Discussion
Ideally, claims regarding an added value of a new medicine
should be based on the results of comparative trials [3, 10].
However, in a previous study we found that nearly one out
of two new medicines had been studied in a randomised
active control trial [8]. Further analysis of the data on
comparative efficacy revealed that an improvement was
demonstrated for only one out of ten new medicines.
Despite this small number, the conclusion cannot simply be
drawn that advances in pharmacotherapy are restricted to
these new medicines. Nevertheless, our results suggest that
there is sufficient reason to adopt a critical attitude towards
the claims of pharmaceutical companies regarding the
added value of their new products.
A number of observations can be made regarding this
result. First, our analysis excluded new medicines for which
no alternative was available and for which, inevitably, a
comparative trial was lacking. However, as such medicines
were developed as the first medicinal therapy for life-
threatening or serious diseases, such as orphan drugs, they
Table 1 New medicines (1999–2005) with an improved efficacy
New medicine Indication Comparator
Bimatoprost Glaucoma Timolol
Capecitabine Colorectal cancer 5-FU/Folonic acid
Emtricitabine HIV-infections (combination) Stavudine
Fondaparinux Prevention of venous thromboembolic events Enoxaparine
Insulin aspart Diabetes mellitus type 1 Insulin regular human
Insulin glulisine Diabetes mellitus type 2 Insulin regular human
Lopinavir HIV-infections (combination) Nelfinavir
Peginterferon alfa 2a Chronic hepatitis C Interferon alfa 2b Interferon alfa 2a
Peginterferon alfa 2b Chronic hepatitis C Interferon alfa 2b
Tipranavir HIV-infections (combination) Protease inhibitors
Travoprost Glaucoma Timolol
Voriconazole Invasive aspergillosis Amfotericin B (conv)
Zoledronic acid Hypercalcaemia (tumour-induced) Pamidronate
HIV, Human immunodeficiency virus
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treatment of patients. Secondly, we only focussed on
differences in efficacy and not on properties such as safety,
applicability or convenience of administration. The reason
for this approach is that main/pivotal trials are particularly
used for demonstrating efficacy. Nevertheless, new medi-
cines whose efficacy is equivalent or noninferior may still
have advantages in terms of safety. An example of this is
tenecteplase, which is used in the treatment of suspected
myocardial infarction; based on a study of 17,005 patients,
it shows an equivalence comparable to alteplase, but a
better safety profile [11].
Another reason for the small number of innovations is
that in terms of being granted market authorisation, the
demonstration of advantages is not an objective in itself.
Consequently, there is no need or requirement to conduct a
trial with such an objective. Moreover, pharmaceutical
companies would be taking a substantial risk to do so, as
failure to demonstrate superiority over a less expensive
existing drug could be a financial disaster. The alternative—
that a positive result could be expected to lead to substitution
of the comparator—appears to carry less weight.
We should note that whether the 13 medicines in our
analysis are really a therapeutic improvement depends on a
sound review of all relevant properties, the clinical relevance
of the differences and the appropriateness of the comparator.
It is always important to meticulously add up all of the
advantages and disadvantages. This also applies to the
medicines in our study, as least as far as it is possible to
assess these medicines using the data in the EPAR. For most
studies, the EPAR does not provide the basic details of trial
design and results in a uniform fashion.
According the EPAR, the efficacy of bimatoprost and
travoprost is superior to that of timolol in the treatment of
glaucoma, but the safety profiles of the former are inferior
due to a higher frequency of ocular side effects. The trial on
tipranavir demonstrated a superior antiviral activity, but
also a higher frequency of hepatic events and lipodys-
trophy. Comparative efficacy is always linked to a specific
comparator, therapeutic indication and type of patients. In
naive human immunodeficient virus (HIV)-infected
patients, emtricitabine was more efficacious than stavudine
but less efficacious than lamivudine; in experienced
patients, lamivudine and stavudine had equal efficacy. In
terms of the appropriateness of the comparator, we can
conclude that in this study the choice of the comparator in
the trials that demonstrated superiority was in line with
recommendations on standard treatment [12].
Another issue in critical evaluations of demonstrated
superiority is the choice of the primary clinical endpoint. A
composite endpoint was used for fondaparinux; an analysis
of all the endpoint events reveals that the incidence of
symptomatic venous thromboembolic events, including
pulmonary embolism, was not significantly different between
treatment groups [13, 14].
It should also be realised that drawing a conclusion of
superiority based on a statistically significant difference
says nothing about the practical significance of the
medicine. The absolute differences in the change in
glycated haemoglobin (HbA1c) levels that were demon-
strated for insulin aspart and insulin glulisine compared to
regular insulin were, at best, of limited clinical relevance.
Moreover, there was no relevant difference in terms of the
incidence of hypoglycaemic events. In this context, it is
interesting to follow developments in the prescription of
fast-acting insulin in the treatment of diabetes, as the results
of clinical studies may not always be reflected in practice
[15, 16]. For prescription data, we used the GIP database of
the Health Care Insurance Board of the Netherlands. This
database contains data on prescriptions for extramural
medicines. This information was obtained from health
insurance organisations and is based on a sample of more
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Graph 1 Trend in the number of prescriptions for fast-acting insulins.
After the introduction of insulin aspart in 1999, there was a decrease
in the number of prescriptions for soluble human insulin; however, use
of the latter had been decreasing since the introduction of insulin
lispro in 1996. Since 2004, insulin aspart is the most prescribed fast-
acting insulin. The introduction of insulin glulisine in 2005 has had
little impact on the number of prescriptions for the other insulins
Eur J Clin Pharmacol (2010) 66:445–448 447than 12 million people. Graph 1 shows the trends in the
usage of human insulin and fast-acting insulins before and
after the introduction of insulin aspart. The degree to which
insulin aspart is used cannot be solely explained by the
results of the premarketing trials. The more rapid onset and
shorter duration of action of the insulin analogue is thought
to facilitate a more flexible life style in comparison with the
use of soluble human insulins [17]. However, this prescrip-
tion practice should also apply to insulin lispro, which can
be regarded as being comparable to insulin aspart [18].
The significant advantages and disadvantages of new
medicines may only become evident during the course of
time, on the basis offurther study and experience. This means
that assessing the added value of a new medicine is not a one-
off incident but a continuous process that is supported by
monitoring usage by means of prescription data.
This study shows and discusses how proven superiority,
as shown through well-demonstrated advantages in efficacy
at an early stage of drug development, is the exception
rather than the rule. The absence of evidence for differences
between medicines does not necessarily mean that there are
no differences. Insight into differences and similarities
between medicines, however small they may be, is
important in order to be able to make the right choice for
the right patient in clinical practice. Therefore, optimal
pharmacotherapy would benefit from more comparative
research in the development of new medicines. This study
also shows that the results of comparative trials should be
critically evaluated in terms of their specific value to clinical
practice. To this end, prescription data may be helpful.
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